A highly selective inhibitor of IκB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection

Transplantation

Volumn 77, Issue 7, 2004, Pages 1090-1094

  Townsend, Robert M ^a,b   Postelnek, Jennifer ^a   Susulic, Vojkan ^a   McIntyre, Kim W ^a   Shuster, David J ^a   Qiu, Yuping ^a   Zusi, F Christopher ^a   Burke, James R ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 345541; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; I KAPPA B KINASE; INTERLEUKIN 2; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INHIBITION; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CADAVER; CD40 LIGAND; ENZYME INHIBITORS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; I-KAPPA B KINASE; IMIDAZOLES; INTERLEUKIN-2; MICE; MICE, INBRED STRAINS; PROTEIN-SERINE-THREONINE KINASES; QUINOXALINES;

EID: 1942504246     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000118407.05205.05     Document Type: Article

References (17)

1. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
2. Judge TA, Tang A, Spain LM, et al. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996; 156: 2294.
3. Bolling SF, Lin H, Turka LA. The time course of CTLA4-Ig effect on cardiac allograft rejection. J Surg Res 1996; 63: 320.
4. Kirk A, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94: 8789.
5. Imagawa DK, Millis JM, Olthoff KM, et al. Anti-tumor necrosis factor antibody enhances allograft survival in rats. J Surg Res 1990; 48(4): 345.
6. Kirkman RL, Barrett LV, Gaulton GN, et al. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. Transplantation 1985; 40(6): 719.
7. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994; 10: 405.
8. Bauerle PA, Baltimore D. NF-κB: ten years after. Cell 1997; 87: 13.
9. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109: S81.
10. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003; 278: 1450.
11. Song HK, Noorchashm H, Lieu YK, et al. In vivo MLR: a novel method for the study of alloimmune responses. Transplant Proc 1999; 31: 834.
12. Fulmer RI, Cramer AT, Liebert RA, et al. Transplantation of cardiac tissue into the mouse ear. Am J Anat 1963; 113: 273.
13. Andreakos E, Smith C, Monaco C, et al. IκB kinase 2 but not NF-κB-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood 2003; 101: 983.
14. Isobe M, Yagita H, Okumura K, et al. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255(5048): 1125-1127.
15. Khoshnan A, Tindell C, Laux I, et al. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000; 165: 1743-1754.
16. Saklatvala J. Glucocorticoids: do we know how they work? Arthritis Res 2002; 4: 146-150.
17. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-541.